Given the favourable overall results in this series and recent analysis of our results in patients with a poorer prognosis based on FDG PET/CT (manuscript in preparation), we have increasingly used PRCRT as first-line treatment in patients with progressive tumours who remain amenable to PRCRT as a result of adequate SSTR expression at all known sites of disease irrespective of Ki-67 (including grade 2 NET and grade 3 neuroendocrine carcinoma). The gene discussed is MKI67; the disease is neoplasm.